• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
    • Overview
    • Cision Communications Cloud®
    • Monitoring
    • Distribution
    • Multimedia
    • Measurement & Analytics
    • IR
  • Contact
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
    Advanced Search
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics
  • Business
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Measurement & Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Measurement & Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution Français English Français


News provided by

Health Canada

Aug 18, 2018, 20:23 ET

Share this article

Share this article


Update – August 21, 2018
This advisory has been updated to clarify the list of products that are NOT being recalled by adding a new column to the table (Lot #), and adding Teva Canada and Pro Doc Ltée products that are NOT being recalled. 
Update – August 21, 2018

OTTAWA, Aug. 18, 2018 /CNW/ - Health Canada is advising Canadians that, as a precautionary measure, Teva Canada is expanding its voluntary recall to include eight additional lots of valsartan products in Canada because they may contain an impurity, N-nitrosodimethylamine (NDMA).

Valsartan is used to treat high blood pressure and heart failure.

This latest action is further to an initial recall of certain valsartan products because of the presence of NDMA in the active ingredient (valsartan). All of the recalled products use a valsartan ingredient manufactured by Zhejiang Huahai Pharmaceuticals in China.

Products containing the valsartan ingredient from Zhejiang Huahai Pharmaceuticals

Health Canada is reviewing the long-term potential health impacts of the NDMA impurity on patients. NDMA is classified as a probable human carcinogen based primarily on animal studies, which means that exposure above acceptable levels over the long term could increase the risk of cancer. The review, which will be completed in the coming weeks, will include an assessment of how much NDMA patients may have been exposed to and for how long. Although Health Canada believes that the NDMA was introduced as a result of a change in manufacturing processes at Zhejiang Huahai Pharmaceuticals in 2012, some Canadian companies may have been using the affected valsartan active ingredient for less time.

The additional Teva Canada products are being recalled after sample testing of the active ingredient by Zhejiang Huahai Pharmaceuticals identified trace levels of NDMA. Testing is ongoing. In the meantime, Health Canada has asked Teva Canada to recall these additional products as a precautionary measure, and to conduct a full investigation to determine the root cause of this most recent issue.

Health Canada is monitoring the recalls. The Department continues to work with the companies and its international regulatory partners to gather and assess information to determine whether additional actions are necessary. We will keep Canadians updated. This includes communicating the results of our health risk assessment once it is complete in the coming weeks.

A complete list of recalled products is provided below.

Products containing valsartan ingredient from other suppliers NOT impacted by the recall

Health Canada has contacted all companies selling valsartan medications in Canada and has confirmed that all of the products NOT being recalled:

  • do not contain valsartan manufactured by Zhejiang Huahai Pharmaceuticals, and
  • were manufactured using different processes from the ones that have been identified as having introduced the impurity.

Health Canada continues to work with companies selling valsartan medications to determine whether their processes are at risk of producing NDMA.

Health Canada is also working with stakeholders to monitor the Canadian supply of valsartan products and alternative medications.

A complete list of products that are NOT recalled is provided below.

What you should do

Patients taking affected valsartan medications should:

  • Continue taking their valsartan medication unless they have been advised to stop by their health care provider.
  • Contact their health care provider as soon as possible to discuss treatment options if they have been using an affected product. Pharmacists may be able to provide a product not affected by the recall, or doctors may prescribe a different medication for their patients' conditions.
  • Ask their pharmacist if they are unsure whether they are using a recalled product.

List of recalled products (products containing the valsartan ingredient from Zhejiang Huahai Pharmaceuticals):

Product name/Active Pharmaceutical Ingredient

DIN

Strength

Lot #

Date added

TEVA-VALSARTAN/HCTZ TABLETS

02356996

80/12.5 mg

35211136A

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357003

160/12.5 mg

35211335A

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357003

160/12.5 mg

35211844R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357011

160/25 mg

35210937R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357011

160/25 mg

35210938R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357011

160/25 mg

35210939R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357011

160/25 mg

35210940R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS

02357038

320/12.5 mg

35211546R

August 17, 2018

TEVA-VALSARTAN/HCTZ TABLETS PP 30s

02357046

320/25 mg

35212731R

July 9, 2018

ACT-VALSARTAN 40MG FC TABLETS 100

02337487

40 mg

K47338

July 9, 2018

ACT-VALSARTAN 80MG FC TABLETS 100

02337495

80 mg

K45370

July 9, 2018

ACT-VALSARTAN 80MG FC TABLETS 100

02337495

80 mg

K47652

July 9, 2018

ACT-VALSARTAN 80MG FC TABLETS 100

02337495

80 mg

K47653

July 9, 2018

ACT-VALSARTAN 80MG FC TABLETS 100

02337495

80mg

K47654

July 9, 2018

ACT-VALSARTAN 160MG FC TABLETS 100

02337509

160 mg

K39691

July 9, 2018

ACT-VALSARTAN 160MG FC TABLETS 100

02337509

160 mg

K44167

July 9, 2018

ACT-VALSARTAN 160MG FC TABLETS 100

02337509

160 mg

K47657

July 9, 2018

ACT-VALSARTAN 160MG FC TABLETS 100

02337509

160 mg

K47658

July 9, 2018

ACT-VALSARTAN 320MG FC TABLETS 100

02337517

320 mg

K44166

July 9, 2018

ACT-VALSARTAN 320MG FC TABLETS 100

02337517

320 mg

K45371

July 9, 2018

SANDOZ VALSARTAN 40 MG

02356740

40 mg

All lots

July 9, 2018

SANDOZ VALSARTAN 80 MG

02356759

80 mg

All lots

July 9, 2018

SANDOZ VALSARTAN 160 MG

02356767

160 mg

All lots

July 9, 2018

SANDOZ VALSARTAN 320 MG

02356775

320 mg

All lots

July 9, 2018

SANIS VALSARTAN 40 MG

02366940

40 mg

All lots

July 9, 2018

SANIS VALSARTAN 80 MG

02366959

80 mg

All lots

July 9, 2018

SANIS VALSARTAN 160 MG

02366967

160 mg

All lots

July 9, 2018

SANIS VALSARTAN 320 MG

02366975

320 mg

All lots

July 9, 2018

PRO DOC LIMITEE VALSARTAN 40 MG

02367726

40 mg

All lots

July 9, 2018

PRO DOC LIMITEE VALSARTAN 80 MG

02367734

80 mg

All lots

July 9, 2018

PRO DOC LIMITEE VALSARTAN 160 MG

02367742

160 mg

All lots

July 9, 2018

PRO DOC LIMITEE VALSARTAN 320 MG

02367750

320 mg

All lots

July 9, 2018

SIVEM PHARMACEUTICAL ULC VALSARTAN 40 MG

02384523

40 mg

All lots

July 9, 2018

SIVEM PHARMACEUTICAL ULC VALSARTAN 80 MG

02384531

80 mg

All lots

July 9, 2018

SIVEM PHARMACEUTICAL ULC VALSARTAN 160 MG

02384558

160 mg

All lots

July 9, 2018

SIVEM PHARMACEUTICAL ULC VALSARTAN 320 MG

02384566

320 mg

All lots

July 9, 2018

List of products that are NOT recalled (products that do NOT contain the valsartan active ingredient from Zhejiang Huahai Pharmaceuticals):

Product name/Active Pharmaceutical Ingredient

DIN

Strength

Lot #

APO-VALSARTAN/HCTZ

02382555

160/12.5 mg

All lots

APO-VALSARTAN/HCTZ

02382563

160/25 mg

All lots

AURO-VALSARTAN

02414201

40 mg

All lots

AURO-VALSARTAN

02414228

80 mg

All lots

AURO-VALSARTAN

02414236

160 mg

All lots

AURO-VALSARTAN

02414244

320 mg

All lots

AURO-VALSARTAN HCT

02408112

80/12.5 mg

All lots

AURO-VALSARTAN HCT

02408120

160/12.5 mg

All lots

AURO-VALSARTAN HCT

02408139

160/25 mg

All lots

AURO-VALSARTAN HCT

02408147

320/12.5 mg

All lots

AURO-VALSARTAN HCT

02408155

320/25 mg

All lots

MYLAN-VALSARTAN

02383527

40 mg

All lots

MYLAN-VALSARTAN

02383535

80 mg

All lots

MYLAN-VALSARTAN

02383551

320 mg

All lots

PMS-VALSARTAN

02312999

40 mg

All lots

PMS-VALSARTAN

02313006

80 mg

All lots

PMS-VALSARTAN

02313014

160 mg

All lots

PMS-VALSARTAN

02344564

320 mg

All lots

RAN-VALSARTAN

02363062

40 mg

All lots

RAN-VALSARTAN

02363100

80 mg

All lots

RAN-VALSARTAN

02363119

160 mg

All lots

DIOVAN

02270528

40 mg

All lots

DIOVAN

02289504

320 mg

All lots

DIOVAN VALSARTAN

02236809

160 mg

All lots

DIOVAN VALSARTAN

02244782

160 mg

All lots

DIOVAN VALSARTAN

02236808

80 mg

All lots

DIOVAN VALSARTAN

02244781

80 mg

All lots

DIOVAN VALSARTAN HCT

02241900

80/12.5 mg

All lots

DIOVAN VALSARTAN HCT

02241901

160/12.5 mg

All lots

DIOVAN VALSARTAN HCT

02246955

160/25 mg

All lots

DIOVAN VALSARTAN HCT

02308908

320 mg

All lots

SANDOZ VALSARTAN HCT

02356694

80/12.5 mg

All lots

SANDOZ VALSARTAN HCT

02356708

160/12.5 mg

All lots

SANDOZ VALSARTAN HCT

02356716

160/25 mg

All lots

SANDOZ VALSARTAN HCT

02356724

320/12.5 mg

All lots

SANDOZ VALSARTAN HCT

02356732

320/25 mg

All lots

SANIS VALSARTAN HCT

02367009

80/12.5 mg

All lots

SANIS VALSARTAN HCT

02367017

160/12.5 mg

All lots

SANIS VALSARTAN HCT

02367025

160/25 mg

All lots

SANIS VALSARTAN HCT

02367033

320/12.5 mg

All lots

SANIS VALSARTAN HCT

02367041

320/25 mg

All lots

SIVEM PHARMACEUTICALS ULC VALSARTAN HCT

02384736

80/12.5 mg

All lots

SIVEM PHARMACEUTICALS ULC VALSARTAN HCT

02384744

160/12.5 mg

All lots

SIVEM PHARMACEUTICALS ULC VALSARTAN HCT

02384752

160/25 mg

All lots

SIVEM PHARMACEUTICALS ULC VALSARTAN HCT

02384760

320/12.5 mg

All lots

SIVEM PHARMACEUTICALS ULC VALSARTAN HCT

02384779

320/25 mg

All lots

TEVA-VALSARTAN

02356643

40 mg

All lots

TEVA-VALSARTAN

02356651

80 mg

All lots

TEVA-VALSARTAN

02356678

160 mg

All lots

TEVA-VALSARTAN

02356686

320 mg

All lots

TEVA-VALSARTAN/HCTZ

02356996

80/12.5 mg

All lots except for the recalled lot 35211136A

TEVA-VALSARTAN/HCTZ

02357003

160/12.5 mg

All lots except for the recalled lots  35211335A  and 35211844R-

TEVA-VALSARTAN/HCTZ

02357011

160/25 mg

All lots except for the recalled lots 35210937R  35210938R

35210939R  35210940R

TEVA-VALSARTAN/HCTZ

02357038

320/12.5 mg

All lots except for the recalled lot 35211546R

TEVA-VALSARTAN/HCTZ

02357046

320/25 mg

All lots except for the recalled lot 35212731R

PRO DOC VALSARTAN /HCTZ

02367769

80/12.5 mg

All lots

PRO DOC VALSARTAN /HCTZ

02367777

160/12.5 mg

All lots

PRO DOC VALSARTAN /HCTZ

02367785

160/25 mg

All lots

Related Links

  • Health Canada advisory (2018-07-09): Several drugs containing valsartan being recalled due to contamination with a potential carcinogen

Également disponible en français

SOURCE Health Canada

For further information: Media Inquiries: Health Canada, (613) 957-2983; Public Inquiries: (613) 957-2991, 1-866 225-0709

Modal title

Organization Profile

Health Canada

    Also from this source

  • Government of Canada announces $16.5 million to support harm...

  • /R E P E A T -- Notice to the media - Government of Canada to...

  • Notice to the media - Government of Canada to announce funding...

Related Organization(s)

Government of Canada

    Also from this source

  • Statement from the Chief Public Health Officer of Canada on April ...

  • Minister Schulte and Minister Hajdu announce the appointment of...

  • Project KAKIA Disrupts Criminal Networks in Durham Region...

    Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices

    Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

    About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers

    My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2021 CNW Group Ltd. All Rights Reserved. A Cision company.